The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.
Similar stories
3 outlets
See how this story developed, hour by hour
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
arstechnica.com
23.10.2026
Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report
nytimes.com
22.10.2026
Moderna’s stock tumbles after reported leak of data for cancer vaccine
marketwatch.com
22.10.2026